Location: Virus and Prion Research
Project Number: 5030-32000-118-64-R
Project Type: Reimbursable Cooperative Agreement
Start Date: Oct 1, 2017
End Date: Aug 31, 2018
Correlate the activation status with antiviral responses in porcine monocytic innate immune cells, and to functionally modulate them as a cellular adjuvant/vaccine candidate for antiviral potentiation in vivo.
Activation status of primary cells and ex vivo stimulated cells will be molecularly defined by expression of marker genes and functionally phenotyped for regulation in inflammation and T-cell proliferation. Correlation with antiviral responses will be compared among the subgroups of cells for resistance to viral entrance/replication and to viral suppression in interferon (IFN) production and action. Cell ex vivo manipulation will be conducted by drug/ligand stimulation and virus-vector mediated gene delivery and targeted expression. This will be achieved by the following: 1. Systematically characterize the activation status and genome-wide determine signature genes potentially regulating the activation status in porcine monocytic innate immune cells. 2. Correlate cell activation status with PRRSV pathogenicity in ex vivo stimulated cells and in primary cells isolated from virus-infected pigs. 3. Develop a prototypic adjuvant/vaccine system based on functional modulation of activation statuses in porcine monocytic innate immune cells.